OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Cecchini on Etrumadenant-Based Combinations in Previously Treated mCRC

August 26th 2024

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Dr Saad on the Potential Predictive Value of IL7 SNPs in RCC

August 26th 2024

Eddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.

Dr Devoe on Next Steps for Evaluating ELI-002 7P in MRD+ KRAS-Mutant PDAC and CRC

August 26th 2024

Craig E. Devoe, MD, MS, discusses next steps for assessing the ELI-002 7P vaccine in patients with MRD–positive, KRAS-mutant PDAC and CRC.

Dr Kelly on Ongoing Trials in Patients With GIST

August 26th 2024

Ciara Kelly, MBBCh, BAO, discusses ongoing trials to further enhance the treatment of patients with gastrointestinal stromal tumor.

Dr Singhi on Areas of Interest in Metastatic Lung Cancer Research

August 26th 2024

Eric Kumar Singhi, MD, discusses potential areas of research interest in the treatment of patients with metastatic lung cancer.

Dr Yekedüz on the Benefits of Biomarker-Driven Treatment in Kidney Cancer

August 26th 2024

Emre Yekedüz, MD, discusses key takeaways from IMmotion010, highlighting the importance of biomarker-driven treatment in patients with kidney cancer.

Dr Koff on BTK Inhibitors vs Venetoclax-Based Regimens in First-Line CLL

August 23rd 2024

Jean L. Koff, MD, MS, discusses considerations around using BTK inhibitors vs venetoclax-based regimens in first-line chronic lymphocytic leukemia.

Dr Chambers on the Role of Genetic Testing and PARP Inhibitors in Ovarian Cancer

August 23rd 2024

Laura J. Chambers, DO, discusses the role of genetic testing and PARP inhibitor maintenance therapy for patients with ovarian cancer.

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

August 23rd 2024

Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.

Dr Waks on Ongoing Research in Residual HER2+ Breast Cancer

August 23rd 2024

Adrienne G. Waks, MD, discusses efforts to improve treatment outcomes for patients with HER2-positive breast cancer with residual disease.

Dr Nawfal on the Rationale for Assessing Radiological Tumor Burden in mccRCC

August 23rd 2024

Rashad Nawfal, MD, discusses radiological tumor burden as an independent prognostic factor for survival in metastatic clear cell renal cell carcinoma.

Dr Krishnan on the Role of Cilta-Cel in High-Risk Multiple Myeloma

August 23rd 2024

Amrita Krishnan, MD, discusses the potential role for cilta-cel in early-relapsed, high-risk patients with multiple myeloma.

Dr Dreicer on the Complexities of Prostate Cancer

August 23rd 2024

Robert Dreicer, MD, discusses his presentation from the 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

Dr Kelly on the Evaluation of the Combination of Ripretinib and DCC-3116 in GIST

August 23rd 2024

Ciara Kelly, MBBCh, BAO, discusses the evaluation of DCC-3116 in combination with ripretinib in advanced gastrointestinal stromal tumor.

Dr Danilov on Unmet Needs for Various CLL Subgroups

August 22nd 2024

Alexey Danilov, MD, PhD discusses unmet needs for patients with chronic lymphocytic leukemia.

Dr Morgans on Considerations for Treating nmCRPC in the Community Setting

August 22nd 2024

Alicia Morgans, MD, MPH, discusses considerations for oncologists treating patients with nonmetastatic castration-resistant prostate cancer in the community setting.

Dr O’Brien on Tucatinib Plus Trastuzumab/Capecitabine for Leptomeningeal Metastases in HER2+ Breast Cancer

August 22nd 2024

Barbara Jane O’Brien, MD, discusses tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases in HER2-positive breast cancer.

Dr Nanda on Treatment De-Escalation in HER2+ Breast Cancer and TNBC

August 22nd 2024

Rita Nanda, MD, discusses efforts to de-escalate adjuvant therapy for patients with select breast cancers who responded to neoadjuvant therapy.

Dr Hamilton on the Safety Profile of ADCs in HER2-Low and -Ultralow Breast Cancer

August 22nd 2024

Erika P. Hamilton, MD, discusses the safety profile of ADCs in patients with hormone receptor–positive, HER2-low and -ultralow breast cancer.

Dr McGregor on Challenges and Future Research Directions in ccRCC

August 22nd 2024

Bradley McGregor, MD, discusses ongoing treatment challenges and future research directions in clear cell renal cell carcinoma.